Navigation Links
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
Date:6/1/2009

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are delighted to welcome Clare to our management team," said Ms. Natalicchio. "Clare's extensive expertise in national healthcare customer management, contracting and distribution will be a great asset as we expand our commercial organization and prepare for the launch of ataluren."

"I am excited to join PTC," commented Ms. Kennedy. "The company has shown an exemplary advancement of its diverse pipeline and I look forward to being part of the commercial organization with a goal to bring PTC's innovative therapies to patients."

Prior to joining PTC, Ms. Kennedy spent 16 years at Pfizer, most recently as Vice President of Account Planning, overseeing national account management, customer contracting and product access in the U.S. for the company's $21 billion portfolio. Ms. Kennedy was responsible for U.S. sales in various areas including commercial health plans, pharmacy benefit management companies, long-term care, employers, and federally-funded programs. Prior to Pfizer, Ms. Kennedy started several small businesses involved in preventive health care and clinical research. She received an A.A.S. in Nursing from Long Island College Hospital, a B.S. in Health Science from St. Francis College and a M.S. in Health Management from the American University Sc
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
2. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
7. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
8. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
9. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
10. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
11. Orexigen(R) Therapeutics to Present at Upcoming Meetings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...alif., Nov. 30 BioMarin ...ay that the Food and Drug Administration (FDA) has...ridine (3,4-DAP), amifampridine phosphate, for the...Syndrome (LEMS). 3,4-DAP has previously received ...ber 2009, the Committee for Medicinal Products for...
(Date:11/30/2009)... and COPENHAGEN, Nov. 30 Exiqon A/...hat the Harvard Medical School ICCB-Longwood Scree...croRNA Screening Center of Excellence. ICCB-L sup... associated hospitals and institutions, for high-t...raries. ,, MicroRNAs are a novel class of small...
(Date:11/30/2009)... , AMSTERDAM, November 30 /PRNew...publisher of scientific, medical and technical pro...nch of Embase, its comprehensive biomedical,databa...m more than 7,000,active, peer reviewed journals. ...e advancement of new biomedical,and pharmaceutical...
(Date:11/27/2009)...RHAM, N.C., Nov. 27 Cromoz Inc., l...ter-soluble carbon nanotube-based cancer drug deli... carbon nanotubes, which have functional groups on... drugs, was developed in partnership with the Indi...n nanotubes serves as a drug delivery vehicle with...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...UNSWICK, N.J., July 7 Senesco,Technologies, Inc. ...nnounced,that the Company recently closed on the r...private placements with YA Global Investments, LP ...s, Inc. ("Stanford"). Senesco,has now received the...ion,private placements of secured convertible debe...
...es data confirms that the risk of mortality faced ...wer than the national average, EL SEGUNDO, Calif....y care services for those diagnosed with chronic,k...eeds national averages,with regard to patient qual... Measures Report published in 2006 by the Centers ...
... The Association of American M...s "Industry Funding of Medical Education"... but also provides guidelines to help medical scho...ationships with industry. An important element of ...riting versus transparent writing collaboration in...
Other Biology Technology:Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing 2Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing 3Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 2Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 3ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications 2ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications 3
(Date:11/30/2009)...The Editors of The Journal of Experimental Biolog...rom Centre National de la Recherche Scientifique (... the winner of this year,s JEB Outstanding Paper... outstanding achievement and is intended to encour...EB Editor-in-Chief, and adds that ,we truly appre...
(Date:11/30/2009)...As global temperatures continue to rise scientists...standing how species respond and adapt. In a paper... Dr Francisco Rodriguez-Trelles and Dr Miguel Rodr... global warming of approximately 0.6˚C has al... challenge facing ecologists and evolutionary biol...
(Date:11/30/2009)...If you ever thought the stress of seeing your exte...oubad news: a new research report in the December ...ogy ( http://www.jleukbio.org ) shows that you mi...he same study might lead to entirely new treatment...rthritis, and eczema under control. That,s because...
Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4How can scientists measure evolutionary responses to climate change? 2Seeing family for the holidays? Scientists discover how the stress might kill you 23SBio Inc to Report 2009 Third Quarter Earnings on November 12 2009 14616 13SBio Inc to Report 2009 Third Quarter Earnings on November 12 2009 14616 2Phase 2 Data From Oral NKTR 118 Presented at American College of Gastroenterology in San Diego 5752 1Phase 2 Data From Oral NKTR 118 Presented at American College of Gastroenterology in San Diego 5752 2Phase 2 Data From Oral NKTR 118 Presented at American College of Gastroenterology in San Diego 5752 3Phase 2 Data From Oral NKTR 118 Presented at American College of Gastroenterology in San Diego 5752 4URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4
...al breakthrough in verifying ... Graphic Security Systems,Corporation (GSSC) and F...ld,s first self-authenticating passport. It was in...ebruary 1, 2008., FCO, the French security printe... optical decoder page in the passport opposite the...
...farmers. The difference is that ants are farming f... at the Smithsonians National Museum of Natural Hi... of the journal Proceedings of the National Academ...cultural abilities of ants and how these abilities...g, the scientists were able to construct an evolut...
... likely to die than female infants, a fact that is... reveals a new study by researchers from Universit...ornia. , The paper, which will be published onlin...gs of the National Academy of Sciences, analyzes 1... of years. It finds that the gender gap in infant ...
Other Biology News:FCO and GSSC Team to Create World's First Self-Authenticating Passport 2Smithsonian's National Museum of Natural History reveals ants as fungus farmers 2Baby boys are more likely to die than baby girls 2
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...an isotonic, balanced salt solution. It is routine...ich permits the storage of whole blood at refriger... usage, an equal volume of blood is collected into...ughly, mixed. The solution is placed in a refriger...
...ve useful for routine procedures. Hollandes contai...able and will decalcify small bone specimens. Tiss...ccessfully with most stains, and the cupric acetat...nes and cosinophil and endocrine cell granules so ...
Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: